Efficacy and Safety of Chidamide in CBF Leukemia

  • End date
    Dec 23, 2022
  • participants needed
  • sponsor
    Institute of Hematology & Blood Diseases Hospital
Updated on 23 January 2021


In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC) or high-dose cytarabine plus chidamide.The safety and efficacy of chidamide is evaluated.


In this open-label, randomized, prospective clinical trial, CBF AML(including AML1-ETO or CBF-MYH11 mutated patients) patients who have reached CR are randomised into two groups and receive HDAC or high dose of cytarabine plus chidamide.

In experimental group, patients receive cytarabine at a dose of 3g//d on the first, third and fifth day and chidamide at a dose of 20mg/d twice a week for 3 months.Patients in control group only receive cytarabine at the same dose.

The safety and efficacy of chidamide is evaluated. The primary outcome is relapse-free survival rate after treatment.

Condition Acute myeloid leukemia, Acute Myelogenous Leukemia (AML), Acute myeloid leukemia, Acute Myelogenous Leukemia (AML), acute myelogenous leukemia, anll, acute myeloblastic leukemia
Treatment cytarabine, Chidamide
Clinical Study IdentifierNCT03031262
SponsorInstitute of Hematology & Blood Diseases Hospital
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Age of 14 to 55 years old
Patients that meet the diagnostic criteria(WHO 2008 criteria) of AML (except APL subtypes) and with AML1-ETO or CBF-MYH11 mutation
Reached CR after induction regimen
ECOG score of 2
Patients with eligible laboratory examination including liver,renal and heart function
Adult patients are willing to participate in the study and sign the informed consent by themselves or by their immediate family. Patients under 18 years old willing to participate should have their legal guardians sign the informed consent

Exclusion Criteria

Secondary leukemia
Patients had other tumor at active stage or had received radiotherapy or chemotherapy in the last 6 months due to other tumor
Patients with other blood diseases(for example, haemophiliacs) are excluded.However, patients with abnormal blood count, but with undiagnosed MDS or MPD patients are included
Acute panmyelosis with myelofibrosis and myeloid sarcoma patients
With BCR-ABL fusion gene
Pregnant or lactating women
With ineligible renal or liver function
With active cardiovascular disease
Severe infection disease including uncured tuberculosis pulmonary aspergillosis
Patients had central nervous system involvement when they were diagnosed as AML
Patients with epilepsy or dementia or other mental disease who couldn't understand or follow the research
Drugs, medical, mental or social situation may distract patients from following the research or being evaluated the results
Patients with other factors which were considered unsuitable to participate in the study by the investigators
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note